Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc (NQ: CMND )

1.670 -0.040 (-2.35%)
Streaming Delayed Price Updated: 3:35 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 658,917
Open 1.690
Bid (Size) 1.660 (5)
Ask (Size) 1.680 (20)
Prev. Close 1.710
Today's Range 1.573 - 1.725
52wk Range 0.9205 - 16.19
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
Via Benzinga

Performance

YTD
-39.94%
-39.94%
1 Month
+35.76%
+35.76%
3 Month
+41.74%
+41.74%
6 Month
+46.47%
+46.47%
1 Year
-86.80%
-86.80%

More News

Read More
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024
Via InvestorPlace
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Why Is SciSparc (SPRC) Stock Up 25% Today?
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Dow Jumps 400 Points; US Retail Sales Flat For June
Via Benzinga
Topics Stocks
Exposures US Equities
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Day Trading My Way From Red To Green
Via Talk Markets
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
What's Going On With Clearmind Medicine Stock Tuesday?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Clearmind Medicine Stock Is Moving Higher
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Applies to Cease Being a Reporting Issuer in Canada
From Clearmind Medicine Inc.
Via GlobeNewswire
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.